InspireMD (NYSE:NSPR) Director Scott Ward Buys 15,995 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) Director Scott Ward acquired 15,995 shares of InspireMD stock in a transaction dated Wednesday, May 6th. The stock was purchased at an average price of $1.15 per share, for a total transaction of $18,394.25. Following the completion of the acquisition, the director directly owned 163,841 shares in the company, valued at approximately $188,417.15. This represents a 10.82% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

InspireMD Trading Down 0.9%

Shares of NSPR opened at $1.15 on Friday. InspireMD, Inc. has a twelve month low of $1.02 and a twelve month high of $2.93. The firm’s fifty day simple moving average is $1.51 and its 200-day simple moving average is $1.75. The firm has a market capitalization of $53.93 million, a price-to-earnings ratio of -1.53 and a beta of 0.82.

Institutional Investors Weigh In On InspireMD

Several hedge funds and other institutional investors have recently bought and sold shares of NSPR. Creative Planning acquired a new stake in InspireMD during the 2nd quarter worth $44,000. Raymond James Financial Inc. raised its stake in InspireMD by 28.9% during the 2nd quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock worth $101,000 after acquiring an additional 10,000 shares in the last quarter. Rosalind Advisors Inc. raised its stake in InspireMD by 0.6% during the 2nd quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company’s stock worth $5,196,000 after acquiring an additional 14,109 shares in the last quarter. Soleus Capital Management L.P. raised its stake in InspireMD by 99.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 1,886,207 shares of the company’s stock worth $4,282,000 after acquiring an additional 940,831 shares in the last quarter. Finally, Courier Capital LLC raised its stake in InspireMD by 83.3% during the 3rd quarter. Courier Capital LLC now owns 55,000 shares of the company’s stock worth $133,000 after acquiring an additional 25,000 shares in the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on NSPR shares. Maxim Group started coverage on shares of InspireMD in a report on Monday, February 2nd. They issued a “buy” rating and a $6.00 price objective on the stock. Piper Sandler restated an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of InspireMD in a report on Tuesday. Loop Capital set a $5.00 price objective on shares of InspireMD in a report on Tuesday, February 24th. Finally, Lake Street Capital set a $4.00 price objective on shares of InspireMD in a report on Monday. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, InspireMD has a consensus rating of “Buy” and a consensus target price of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.